Stockscreener 앱 받기
3.5553
2.22%
-0.0809
시간 외 거래:
3.56
0.0047
+0.13%
전일 마감가:
$3.6362
열려 있는:
$3.51
하루 거래량:
2,871
Relative Volume:
0.22
시가총액:
$64.44M
수익:
-
순이익/손실:
$-9.46M
주가수익비율:
-6.1415
EPS:
-0.5789
순현금흐름:
$-8.70M
1주 성능:
+12.51%
1개월 성능:
+3.06%
6개월 성능:
-15.15%
1년 성능:
+14.69%
1일 변동 폭
$3.4914
$3.61
1주일 범위
$3.09
$3.7244
52주 변동 폭
$2.5209
$7.00
알테리티 테라퓨틱스 Stock (ATHE) Company Profile
Compare ATHE vs VRTX, REGN, ARGX, ALNY, INSM
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ATHE
Alterity Therapeutics Ltd Adr
|
3.5553 | 64.44M | 0 | -9.46M | -8.70M | -0.5789 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
알테리티 테라퓨틱스 Stock (ATHE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-03 | 다운그레이드 | The Benchmark Company | Speculative Buy → Hold |
| 2024-12-12 | 개시 | Maxim Group | Buy |
알테리티 테라퓨틱스 주식(ATHE)의 최신 뉴스
ATA Inc. (NASDAQ:AACG) Sees Large Decline in Short Interest - Defense World
Actelis Networks, Inc. (NASDAQ:ASNS) Sees Large Decline in Short Interest - Defense World
Purple Biotech Stock Scheduled to Reverse Split on Monday, March 2nd (NASDAQ:PPBT) - Defense World
Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) Short Interest Up 188.7% in February - Defense World
Ameritas Investment Partners Inc. Raises Stock Holdings in Kratos Defense & Security Solutions, Inc. $KTOS - Defense World
Analysts Set Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) Price Target at $32.60 - Defense World
Alterity Therapeutics (NASDAQ:ATHE) Upgraded at Zacks Research - Defense World
Compass Minerals International, Inc. (NYSE:CMP) Receives $22.00 Consensus Price Target from Analysts - Defense World
Benjamin Edwards Inc. Acquires 2,629 Shares of iShares Russell 1000 Value ETF $IWD - Defense World
AOT Growth & Innovation ETF (NASDAQ:AOTG) Short Interest Update - Defense World
Allspring Global Investments Holdings LLC Purchases 1,956,470 Shares of Allspring Special Large Value ETF $ASLV - Defense World
Alterity Therapeutics Limited – Sponsored ADR (NASDAQ:ATHE) Sees Significant Drop in Short Interest - Defense World
CaixaBank (OTCMKTS:CAIXY) Hits New 52-Week High – Still a Buy? - Defense World
ProShares Short S&P 500 (NYSEARCA:SH) Sets New 1-Year Low – Here’s Why - Defense World
Alterity Therapeutics (NASDAQ:ATHE) Coverage Initiated by Analysts at Canaccord Genuity Group - Defense World
Alterity Therapeutics Ltd (ADR) trading halted, news pending - MSN
Insights: Alterity Therapeutics Ltd (ASX:ATH) - smallcaps.com.au
Antalpha Platform Holding Company (NASDAQ:ANTA) Short Interest Update - Defense World
Contrasting Alterity Therapeutics (NASDAQ:ATHE) & BioHarvest Sciences (NASDAQ:BHST) - Defense World
CapEx per share of Alterity Therapeutics Ltd. Sponsored ADR – NASDAQ:ATHE - TradingView
Alterity Therapeutics stock rises after positive MSA trial data presented at conference - Investing.com
Alterity Therapeutics (ATHE) Presents Positive Phase 2 Data for ATH434 - Finviz
Alterity Therapeutics (NASDAQ:ATHE) Shares Down 0.5% – What’s Next? - Defense World
Alterity Therapeutics presents ATH434-201 Phase 2 data - TipRanks
Alterity CEO to provide corporate update on ATH434 development - Investing.com
Alterity Therapeutics reports Phase 2 data at MSA Congress By Investing.com - Investing.com South Africa
Alterity Therapeutics announces trading halt - Investing.com
ASX healthcare 2024 winners and losers, plus what’s next for 2025 - Stockhead
symbol__ Stock Quote Price and Forecast - CNN
- SEC.gov
Alterity Therapeutics LtdADR (ATHE) News, Articles, Events & Latest Updates - Stocktwits
Alterity Therapeutics Presents Promising Wearable Sensor Data from the bioMUSE Natural History Study at the American Academy of Neurology By Investing.com - Investing.com India
Alterity Therapeutics Announces 1-for-10 Reverse ADS Split (consolidation) - PR Newswire
Quince Therapeutics (QNCX) Short Interest & Short Float | Updated Mar 2026 - MarketBeat
Ernexa Therapeutics (ERNA) Short Interest Ratio and Volume 2025 - MarketBeat
Alterity Therapeutics Receives U.S. FDA Approval for Investigational New Drug Application for ATH434 for the Treatment of Multiple System Atrophy - Barchart.com
What is the current Price Target and Forecast for Alterity Therapeutics LimitedSponsored ADR (ATHE) - Zacks Investment Research
Mainz Biomed (MYNZ) Short Interest & Short Float | Updated Mar 2026 - MarketBeat
IM Cannabis (IMCC) Short Interest & Short Float | Updated Dec 2025 - MarketBeat
Portage Biotech (PRTG) Short Interest & Short Float | Updated Apr 2026 $PRTG - MarketBeat
Purple Biotech (PPBT) Short Interest & Short Float | Updated Nov 2025 - MarketBeat
ATHE Financial Statements & ChartsAlterity Therapeutics LtdAdr MacroTrends - CMLviz
ATHE Pivot Points, Technical Analysis and Moving AveragesAlterity Therapeutics LtdAdr Technicals - CMLviz
Alterity Therapeutics Stock Price Forecast. Should You Buy ATHE? - StockInvest.us
Check up: A good fortnight to be a small cap health investor - Stockhead
Genprex (GNPX) Short Interest Ratio and Volume 2025 - MarketBeat
iBio (IBIO) Short Interest & Short Float | Updated Jan 2026 - MarketBeat
Integrated BioPharma (INBP) Short Interest Ratio and Volume 2025 - MarketBeat
ESSA Pharma (EPIX) Short Interest Ratio and Volume 2025 - MarketBeat
Immuron (IMRN) Short Interest & Short Float | Updated Dec 2025 - MarketBeat
Check up: Maybe next week will be better? - Stockhead
알테리티 테라퓨틱스 (ATHE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.49%
1.47%
자본화:
|
볼륨(24시간):